BCL2 and Epstein-Barr virus infection: Consistent with dependence of uninfected B cells on these BCL-2 family members predicted by BH3 profiling, treatment with ABT-737 concurrent with EBV infection resulted in an IC50 in proliferating B cells of ~10 nM (Figure 2B–C).